It is the broad, long-term goal of this program to build on and extend the current knowledge in the field of high dose therapy for patients with breast cancer. While the use of high dose therapy with hematopoietic support has resulted in improved outcome in selected patients, the relapse rate in those treated late in the course of their disease remains high. In order to improve the disease free and overall survival for women with breast cancer, the investigators in this renewal of the program project grant application will utilize a translational research approach, bridging the novel experimental concepts and observations made at the laboratory bench to clinical application at the patients' bedside. This program project will focus on the use and understanding of high dose therapies in an attempt to achieve a complete or near complete remission in patients with breast cancer and complement the high dose therapy by the addition of novel manipulations after the high dose therapy in order to improve the clinical outcome of such patients. The theme of this program project focuses on improving the therapeutic results and decreasing the toxicity of high dose combination alkylating agent therapy for breast cancer through a collaborative and integrated approach involving all the investigators in this program project grant. The three specific research projects are: (1) immunotherapy with antigen specific dendritic cells (DCs) and the measurement of its effect; (2) a multi-center trial of allogeneic bone marrow transplantation (BMT) for breast cancer and testing for a graft-vs.-tumor (GVT) effect; (3) tumor drug resistance and pharmacology of each of the high dose drugs. Each of these projects are related to each other in its scientific and clinical interactions, and these three projects are supported by two cores: A) Administrative and Research Coordination; and B) Biostatistics and Data Management Core. The goal will be to identify the most promising approach or approaches for future studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047741-09
Application #
6124596
Study Section
Subcommittee G - Education (NCI)
Program Officer
Xie, Heng
Project Start
1990-06-01
Project End
2001-11-30
Budget Start
2000-01-18
Budget End
2000-11-30
Support Year
9
Fiscal Year
2000
Total Cost
$1,397,933
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Brennan, Todd V; Lin, Liwen; Huang, Xiaopei et al. (2018) Generation of Luciferase-expressing Tumor Cell Lines. Bio Protoc 8:
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
MacDonald, Kelli Pa; Blazar, Bruce R; Hill, Geoffrey R (2017) Cytokine mediators of chronic graft-versus-host disease. J Clin Invest 127:2452-2463
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
MacDonald, Kelli P A; Hill, Geoffrey R; Blazar, Bruce R (2017) Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129:13-21
Du, Jing; Paz, Katelyn; Flynn, Ryan et al. (2017) Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production. Blood 129:2570-2580
Rowland, Christopher R; Colucci, Lina A; Guilak, Farshid (2016) Fabrication of anatomically-shaped cartilage constructs using decellularized cartilage-derived matrix scaffolds. Biomaterials 91:57-72
Flynn, Ryan; Paz, Katelyn; Du, Jing et al. (2016) Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 127:2144-54
Brennan, Todd V; Lin, Liwen; Brandstadter, Joshua D et al. (2016) Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest 126:207-19
Sung, Anthony D; Sung, Julia A M; Thomas, Samantha et al. (2016) Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clin Infect Dis 63:999-1006

Showing the most recent 10 out of 132 publications